Based on the rapid development of the finished drug business, Jingxin Pharmaceutical is realizing the rapid layout of the long-awaited medical device industry by means of mergers and acquisitions. The marriage with the giants is only the first step in the strategic layout. Recently, six organizations including E Fund, Ruiquan Capital, SDIC UBS, Huaan Fund, Xingye Global Fund, and Guangfa Securities collectively conducted on-site investigations to understand the M&A process.

According to reports, Jingxin Pharmaceutical is still based on the rapid development of the finished drug business. Through its own research and development and foreign mergers and acquisitions, the company now has three major categories of chemical preparations, traditional Chinese medicines and biological preparations, and has formed a core and focused There are breeding echelon series products. The core growth of the company is mainly based on chemical drugs, and the development of finished medicines with distinctive Chinese medicines and biological medicines. Committed to the rapid growth of finished drugs, while maintaining the steady growth of APIs, the APIs are positioned to ensure the formulation business, forming the integration of raw materials and preparations. The company is stepping up the development of the medical device business segment after the merger and acquisition, and actively enters the medical device segment with the giant scorpion as the platform to realize the comprehensive development of the company in the field of medicine and medical devices.

The medical device industry has been paying attention for a long time. The company believes that the future development of the medical device industry is promising. The acquisition of giants is to quickly enter the field.

Fundamentally, Jubilee has an industry status in the medical display industry, and is the only company in China that can customize display devices for foreign mainstream medical device manufacturers in batches. The domestic market share is also the first among domestic brands. If the acquisition is successful, the company will enter the medical equipment industry with good market prospects. On the basis of the original pharmaceutical R&D and production, the new medical special display equipment production and sales business will help the company to expand and optimize its business and product structure, and realize customer resource sharing. To meet the diversified needs of customers, and to reduce the risk of a single pharmaceutical business operation of listed companies, to achieve the company's comprehensive development in the field of medicine and medical devices.

At present, in the process of national medical improvement, the price reduction of drug bidding is an inevitable trend. It is the same for all production enterprises. Jingxin Pharmaceutical actively faces the work of improving quality and improving production efficiency. The company's own advantages include the production line of preparations. EU certification, multiple products exported to the European market, by distinguishing the quality level, the price reduction of the tender will not change the overall growth trend of the company's preparation products.

In addition, the raw material medicine business is one of the important sectors of the company, and it is also the supporting and guarantee for the development of the company's preparation business. The company's new preparations must have their own supporting raw materials for the development and listing of the new preparations. Therefore, the company has positioned the raw materials to ensure the preparation business and form raw materials. The formulation is integrated and developed. The company started from raw material medicine. After years of development, it has also formed its own competitive advantage. In the future, it will increase the development of new technologies and break through the development of raw material medicine business with new technology breakthroughs.

In order to achieve the company's sustained and rapid development, mergers and acquisitions have been one of the company's long-term strategic work. The company's M&A work is centered on the implementation of the company's strategy, and it is a marriage with the giants. The company has a certain industry position and competitiveness in the field of medical device segmentation. It uses the company's capital and marketing network platform to achieve rapid breakthrough and development; the company uses the giant platform, To achieve comprehensive development in the field of medicine and medical devices, M&A work will continue to be implemented around the company's sustained and rapid development strategy.

According to the current situation analysis, the company's key products have certain market competitiveness and good development prospects. The cardiovascular drug rosuvastatin continued to maintain rapid growth; simvastatin enjoyed a separate quality level in several provinces such as Zhejiang in the new round of drug bidding, and the growth was obvious; pitavastatin had obtained production approval and had an exclusive dosage form. In the market cultivation period, it is expected to play a very good complementary role. The new digestive drug rehabilitation liquid is produced by only four manufacturers. The future competition pattern is stable, and the market scale is expanding rapidly. It is expected to enter a period of rapid growth; Bacillus licheniformis bacteria enter the national drug list, and the current competitor is only Northeast Pharmaceutical. A better competitive landscape is expected to begin to contribute to the performance. Neuropsychiatric drugs are also an important preparation product line for the company's future development. The antidepressant preparation of sertraline hydrochloride has become the first brand in China. The newly listed product for the treatment of epilepsy, levetiracetam, is one of the first domestic manufacturers. The market prospect is huge, and there is still a trial of rivastigmine, for the treatment of moderate to severe Alzheimer's drugs. With the advent of the age of aging, the development of such psychotropic drugs will be even larger.

Enhance Memory Ingredients

Enhance Memory Ingredients,Natural Phosphatidylserine,Anti-Oxidation Phosphatidylserine Powder,Soybean Extract Phosphatidylserine Powder

Xi'an XJeson Biotech Co., Ltd , https://www.xjesonbio.com